Tag: Intellectual Property
The Intersection of Antitrust, Patents, and FDA Law: The TriCor Litigation
This article is part of a Chronicle. See more from this Chronicle
Richard Epstein, Mar 26, 2009
The purpose of this brief essay is to address...
DG Competition’s Preliminary Report on the Pharma Sector Inquiry: A Need...
This article is part of a Chronicle. See more from this Chronicle
David Hull, Feb 25, 2009
Much of the discussion at the time of the...
The Interplay of Patenting Strategies and Competition Law in the Pharmaceutical...
This article is part of a Chronicle. See more from this Chronicle
Kristina Nordlander, Stephen Spinks, Feb 24, 2009
In the presentation of its Preliminary Report...
The EC’s Investigation into the Pharmaceutical Sector: Trouble Ahead at the...
This article is part of a Chronicle. See more from this Chronicle
David Hull, Nov 12, 2008
Efforts by innovative pharmaceutical companies to protect their markets...
Schumpeterian Competition and Antitrust
Herbert Hovenkamp, Nov 01, 2008
Joseph Schumpeter´s vision of competition saw it as a destructive process in which effort, assets, and fortunes were continuously destroyed...
Microsoft (EC) and Duty to Deal: Exceptionality and the Transatlantic Divide
Eleanor Fox, Apr 24, 2008
This article examines Microsoft´s offense in withholding full information to its workgroup server operating systems rivals so that they could...
The Logic and Limits of Ex Ante Competition in a Standard-Setting...
Damien Geradin, Anne Layne-Farrar, Apr 19, 2007
Some scholars have questioned the process by which cooperative standards are typically set, worrying about the potential for...
What The Rambus Ruling Means For Intellectual Property In Standard Setting
This article is part of a Chronicle. See more from this Chronicle
Anne Layne-Farrar, Feb 15, 2007
On February 5 the U.S. Federal Trade Commission (FTC)...
